Techno Drugs Limited’s private company primarily focuses on specialized products, offering a range of products in Oncology, Anesthesia, Birth Control Pills, Injections, and modern technology Implant sticks (for 5-year birth control). The company was registered as a private company in 2009 and converted into a public company in 2019. Additionally providing veterinary and general human medicines.

Their main medicines include:

Birth Control Medicines: Sukhi 3rd Generation oral pill, Provera Injection, Implant Stick 5 years birth control
Anti-cancer Medicines: Hertin, Zolomide, Eposide
Anesthesia Medicines: Lidocaine plus Inj, Vencuron-10 IV Inj
General Human Medicines: Motilex Suspension, Omsec, Romilac, Cefixon Injection.
Veterinary Medicines: Vermic Inj, Dexavet Inj, Rumen plus pow, Vitazinc Sol

Techno Drugs Limited has been advancing in producing and distributing high-quality medicines. The company’s management director, Mehereen Ahmed, holds a PhD in Oncology from Dhaka University, ensuring expertise in the field. The management team and staff work diligently to ensure quality.

Every year, Techno Drugs Limited supplies the highest amount of birth control medicines in opposition to tenders from the Family Planning Directorate of the Bangladesh Government. With 17 depots across the country, they ensure nationwide distribution. The company also has a “24/7 Monitoring Team” at every level to ensure proper monitoring of all company operations.

With listing on the stock market, Techno Drugs Limited anticipates increased production and sales, benefiting investors and stockholders. Their commitment to corporate governance, job creation, business expansion through IPO funds, and regular dividends to investors aims at socio-economic development in the country and enhancing the country’s reputation in the global pharmaceutical market.

Techno Drugs continues to produce life-saving medicines and is progressing as a profitable company. With various specialized products and a wide range of human and veterinary medicines, they aim for further advancement in the future. Currently, the company’s total capital is approximately 94 crores taka with management holding 63% and the management board having 88% of the shares. Techno Drugs believes that with their capable management and dedicated staff, they will achieve more success in the future, making it a secure investment for investors.

Analyzing the performance of the U.S. stock markets for the week, significant fluctuations were observed across various indices. While the Nasdaq Composite and S&P 500 indices faced declines, the DJIA Index managed to record gains. Conversely, the Russell 3000 and Russell 2000 indices also experienced losses, albeit to varying degrees. Let’s delve deeper into the dynamics shaping the week’s market movements.

Reviewing the U.S. Stock Markets, the Nasdaq Composite, recorded a decent drop of 893 points, reaching a closing value of 15,282 points by the end of the week. Similarly, the S&P 500 index showed a negative trend, losing 156 points to settle at 4,967 points. Meanwhile, DJIA Index experienced a notable hike, adding 3 points during the week and concluding at 37,986 points after a week of gain.

In contrast, Russell 3000 Index saw a losing in week performance, with a slight drop of 89 points to reach 2,840 points by the end of the week.

Moving to Russell 2000 Index, demonstrated a notable shed of 56 points, ending the week at 1,947 points.

In the Outgoing week, the European stock market displayed a varied performance.

Here is the data on the weekly performance of the European Stock Market, The STOXX Europe 600 index, which is considered a leading benchmark for the European market and covers approximately 90 percent of the market capitalization across 17 countries, reported a slight drop of 5.96 points to close at 499.29.

The United Kingdom’s FTSE 100, one of the most widely followed indices in Europe, also showed a significant drop, losing 100 points or finishing the session at 7,895.

In Germany, the DAX 30 index, shed by 438 points to reach 17,737, while France’s CAC 40 increased by 12 points to stop at 8,022 at the end of the trading day.

Italy’s FTSE MIB, which covers the top 40 stocks traded on the Milan Stock Exchange, increased by 158 points to 33,922. However, Spain’s IBEX 35, added by 43 points, to close at 10,729.